Histology Findings after Two Years of Cytology/HPV Co-Testing in Germany

Abstract

Introduction

Since 1 January 2020, diagnostic confirmation of abnormalities detected in the context of cytology/HPV co-testing in cervical cancer screening under the statutory health insurance scheme in women aged 35 and over has been performed according to predefined algorithms. A colposcopy is indicated even in the case of borderline/low-grade cytological changes and/or HPV persistence. In this article we compare the histology findings after primary screening examinations in 2020/21 with those from 2018/19, thus also comparing the results of two different screening approaches.

Patients and Methods

Our analysis included all of the cytology, HPV, and histology results from all primary screening examinations, as well as the resulting diagnostic confirmation and curative cases, that could be obtained by 30 June 2023. In 2018/19 these comprised 650600 cytology and 1804 histology findings, and in 2020/21 there were 491450 cytology and 7156 histology findings. The absolute numbers of histology findings and the percentage ratios of these to all cytological diagnoses are presented with comparison factors.

Results

In 2020/21 there were 5.2 times more histology findings in relation to all previous cytology examinations than in 2018/19, as well as 10.6 times more biopsies, 3.8 times more conizations, and 1.2 times more hysterectomies. There was a particularly high increase in diagnostic confirmation of borderline/low-grade or only HPV-positive findings. With co-testing, 12.7 times more CIN1, 6.4 times more CIN2, and 3.5 times more CIN3 lesions were diagnosed. The proportion of biopsies without dysplasia was 7.6 times higher than in previous years. Cervical carcinomas were diagnosed 1.8 times more frequently, and endometrial carcinomas 0.7 times less frequently.

Conclusion

More CIN lesions were found with co-testing, but the increase in histology findings of low-grade or no dysplasia was far greater than findings of CIN3. Lesions not requiring treatment accounted for 94.4% of biopsy results in 2020/21. The use of computer-assisted LBC with progression markers could reduce this.

Keywords

cervical cancer screening - co-testing - HPV - cytology - LBC - histology

Publication History

Received: 29 November 2023

Accepted after revision: 08 February 2024

Article published online:
10 April 2024

• References/Literatur

• 1 Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Krebsfrüherkennungs-Richtlinie und eine Änderung der Richtlinie für organisierte Krebsfrüherkennungsprogramme: Programm zur Früherkennung von Zervixkarzinomen. Accessed November 26, 2023 at: https://www.g-ba.de/downloads/39–261–3597/2018–11–22_oKFE-RL_Zervixkarzinom.pdf
• 2 Hillemanns P, Friese K, Dannecker C. et al. Prevention of Cervical Cancer.Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) – Part 2 on Triage, Treatment and Followup. Geburtshilfe Frauenheilkd 2019; 79: 160-176 DOI: 10.1055/a-0828-7722. (PMID: 30792546)
• 3 Xhaja A, Ahr A, Zeiser I. et al. Two Years of Cytology and HPV Co-Testing in Germany: Initial Experience. Geburtshilfe Frauenheilkd 2022; 82: 1378-1386 DOI: 10.1055/a-1886-3311. (PMID: 36467972)
• 4 DKG. Jahresbericht der zertifizierten Gynäkologischen Dysplasie-Einheiten und Gynäkologischen Dysplasie-Sprechstunden. Accessed November 26, 2023 at: https://www.krebsgesellschaft.de/jahresberichte.html?file=files/dkg/deutsche-krebsgesellschaft/content/pdf/Zertifizierung/Jahresberichte%20mit%20DOI%20und%20ISBN/qualitaetsindikatoren_gynaekologische-dysplasien_2022-A1_220822.pdf&cid=107843
• 5 Griesser H, Breinl H, Jordan B. Münchner Nomenklatur III: Gynäkologische Dysplasien werden klar zugeordnet. Dtsch Arztebl Ausg A 2014; 111: A640
• 6 Nayar R, Wilbur DC. The Bethesda System for Reporting Cervical Cytology: A Historical Perspective. Acta Cytol 2017; 61: 359-372 DOI: 10.1159/000477556. (PMID: 28693017)
• 7 Klug SJ, Neis KJ, Harlfinger W. et al. A randomized trial comparing conventional cytology to liquid-based cytology and computer assistance. Int J Cancer 2013; 132: 2849-2857 DOI: 10.1002/ijc.27955. (PMID: 23175270)
• 8 Marquardt K, Ziemke P. Co-Test im Zervixkarzinom-Screening: Die erste Runde. Gynäkologie 2022; 55: 867-874 DOI: 10.1007/s00129-022-05014-4.
• 9 Henes M, Mann E, Hirchenhain C. et al. Registry Study of the Working Group on Cervical Pathology and Colposcopy (AGCPC) on the Diagnostic Algorithm for the New Cervical Cancer Screening – Initial Data. Geburtshilfe Frauenheilkd 2023; 83: 1250-1262 DOI: 10.1055/a-2159-7510. (PMID: 37808262)
• 10 Stuebs FA, Koch MC, Dietl AK. et al. Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment. Diagnostics (Basel) 2022; 12: 1748 DOI: 10.3390/diagnostics12071748. (PMID: 35885651)
• 11 Schenck U, Hantschke-Zerbich H, Woellner F. et al. Evaluations of the 2019 Annual Statistics Under the Cervical Cytology Quality Assurance Agreement: 2019 Annual Statistics for Cervical Cytology from 15608413 Women. Geburtshilfe Frauenheilkd 2023; 83: 1235-1249 DOI: 10.1055/a-2134-6740. (PMID: 37808258)
• 12 Ikenberg H, Bergeron C, Schmidt D. et al. PALMS Study Group. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105: 1550-1557 DOI: 10.1093/jnci/djt235.
• 13 Wright jr TC, Stoler MH, Ranger-Moore J. et al. Clinical validation of p16/Ki-67 dual-stained cytology triage of HPV-positive women: Results from the IMPACT trial. Int J Cancer 2022; 150: 461-471 DOI: 10.1002/ijc.33812. (PMID: 34536311)
• 14 Verhoef L, Bleeker MCG, Polman N. et al. Evaluation of DNA methylation biomarkers ASCL1 and LHX8 on HPV-positive self-collected samples from primary HPV-based screening. Br J Cancer 2023; 129: 104-111 DOI: 10.1038/s41416-023-02277-z. (PMID: 37100874)